BSI 507
Alternative Names: BSI-507Latest Information Update: 30 May 2023
Price :
$50 *
At a glance
- Originator Biosion
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD112 receptor antagonists; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 27 Mar 2023 BSI 507 is available for licensing as of 27 Mar 2023. https://www.biosion.com/partnership (Biosion website, March 2023)
- 22 Mar 2023 Preclinical trials in Cancer in USA (Parenteral)